Russell Hoover

Russell Hoover is a Senior Research Fellow at Vertex Pharmaceuticals, where since January 2002, Russell has initiated and advanced two pre-clinical oncology programs, including the first in-class DNA-PK inhibitor VX-984 and a novel non-disclosed project as Biology Lead. These efforts contributed to a significant licensing agreement of four Vertex oncology assets to Merck KGaA. Prior to this role, Russell served as a Postdoctoral Associate at the Whitehead Institute for Biomedical Research from 1998 to 2002. Russell holds a Ph.D. in Cell and Molecular Physiology from the Pennsylvania State University College of Medicine and a Bachelor’s Degree in Biology from Millersville University of Pennsylvania.